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BACKGROUND: HIV associated neurocognitive deficit impairs 
motor activity, neuropsychiatric functioning, daily activity and 
work activity usually due to the immune suppression effect of the 
virus. Sub-Saharan region including Ethiopia is the region with 
the highest burden of HIV. However, a few studies are found on 
this aspect nationally. This study was aimed at determining the 
prevalence and the factors associated with cognitive impairment 
among HIV positive people in Ethiopia who attended Ayder 
Comprehensive Specialized Hospital. 
METHOD: A hospital based cross sectional study was employed on 
234 participants selected using systematic random sampling 
technique. Data was collected thrpugh face-to-face interview, 
observation and document review. International HIV dementia 
scale, activity of daily living scale and Hospital Anxiety and 
Depression scale were used to assess neuro cognitive deficit, 
activity of daily living, anxiety and depression respectively. The 
data was analyzed by using SPSS window 20. 
RESULT: About 88% of the subjects were receiving highly active 
antiretroviral therapy. The magnitude of Neuro cognitive deficit 
was 33.3% (95% CI; 27.7% - 40.6%). Impairment in the activity of 
daily living was observed on 9.8% of the participants. Besides, 
55.6% and 67.1% had anxiety and depressive disorders 
respectively. Late clinical stage of the illness (AOR= 4.2 (95% CI; 
1.19, 14.44)) and impairment in the activity of daily living were 
significantly associated with neurocognitive deficit (AOR= 7.19 
(95% CI; 1.73, 21.83). 
CONCLUSION: A higher prevalence of neurocognitive deficit was 
observed that was related to impaired activity of daily living and 
being in late stages of the illness. Hence, this should be a strong 
alarm for early detection of the problem and consistent review of 
the treatment regimen. 
KEYWORDS: HIV associated Neurocognitive Deficit, Neuro 
cognitive deficit, HIV Associated Dementia, Cognitive Impairment, 
International HIV Dementia Scale, Ethiopia 
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INTRODUCTION   
 
The area with the highest burden of Human 
Immune Deficiency Virus (HIV) that accounts 
for 75% of the case is Sub-Saharan region. 
This is the region with only 12% of the global 
population (1). Neurocognitive deficit (NCD) 
occurs mainly due to HIV among HIV 
positive people (2,3). The problem in sub- 
Saharan area is expected to be large as HIV 
infection and its sequel are prevalent in the 
region (2,4). Previous studies conclude that 
neurocognitive deficit has been found at any 
stage of the illness (5,6,7,8). 
Neurocognitive deficit is a deficit in neurological 
activities, motor activities, psychological 
functioning, daily activities and activities at work 
place. The major cause of morbidity and disability 
among HIV positive people has been accounted to 
NCD, although the problem is rarely studied in the 
region. Deficits in different areas of life such as 
cognitive, motor, emotional and even personality 
changes can be caused by HIV especially lately as 
the disease progression fastens. These problems 
range from the asymptomatic impairments to mild 
forms and to the more severe HIV dementia 
(3,4,9,10,11).    
A Metaanalysis (systematic review) found 
out that in sub-Saharan region, a higher prevalence 
was observed in the pre-highly active 
anterotroviral therapy (HAART) participants in 
which neurocognitive impairment (NCI) pre-
HAART was 42.37%, and among those on 
HAART was 30.39% (2). Respective NCI 
estimates in studies from Uganda were 46.49%. In 
addition, NCI was more common among patients 
with a concomitant psychiatric ailment. And, the 
study concluded that HIV strongly predisposes to 
NCI leading to a huge burden in Sub-Saharan 
Africa (4). 
The more common impairments are the 
asymptomatic and mild forms that are more 
prevalent with advanced age (12). The problem of 
NCD in sub-Saharan area ranges from 20% - 37% 
as reported in prior studies (2,11,13). A report in 
the multi-center international studies that were 
conducted in Thailand, Zaire, Kenya, Brazil and 
Germany revealed that the neuropsychological 
deficit among HIV-positive people ranged from 
13% in Brazil to 19% in Zaire (14,15,16).  
A study conducted in Northern Nigeria in 
2014 in which a total of 418 patients participated 
showed that a total of 21.5% participants were 
found to have cognitive impairment. Using a 
Frascati criterion, 13.3% were found to have HIV 
associated dementia (HAD), 42.2% had mild 
neurocognitive deficit, and 44.4% had 
asymptomatic neurocognitive impairment, within 
this group. Cognitive impairment was significantly 
associated with duration of illness, CD4 count, 
viral load, education, severity of the illness and 
history of complete stopping of HAART in the 
past (17). 
A similar study from India between October 
2011 and September 2012, on 80 HIV-positive 
individuals randomly selected from the ART 
Centre, the patients were clinically examined and 
tested using International HIV dementia scale 
(IHDS). Accordingly, all HIV-positive 
participants who were already on HAART were 
found to have neurocognitive deficit; the overall 
prevalence was 32.5% (18). 
In a similar finding. all participants were 
either in World Health Organization (WHO) 
clinical stage I or stage II of HIV illness and 
87.1% of them were on HAART. The prevalence 
of HIV associated neurocognitive deficit (HAND) 
was 90%. And it was determined by IHDS (19). 
In Malawi and Botswana, studies conducted 
on 106 and 120 patients reported that in the former 
symptomatic neurocognitive impairment was 
present in 15%; 55% fulfilled Frascati criteria for 
asymptomatic neurocognitive impairment (20). As 
well, 38% had severe form of NCD (HIV 
associated dementia) in Botswana that was 
significantly associated with educational level and 
age.  In that study, 24% of the subjects also had 
co- existing depression (21). However, the level of 
education significantly affected performance on 
all three cognitive measures, and age affected 
processing speed and performance on the IHDS. 
Depression and current CD4 count did not affect 
performance on any of the cognitive measures 
(21). 
A study conducted in Ethiopia in 2014 on 
423 HIV positive participants by using IHDS, 
determined that the prevalence of HIV associated 
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dementia (severe form of neurocognitive 
impairment) was 24.8%. Also, low levels of 
education, older age of 50 years or above, co 
morbid opportunistic infection and substance use 
were significantly associated with HIV dementia 
(22). 
Neurocognitive impairment is one of the 
serious problems among HIV-positive people. It 
can lead to morbidity, treatment non- adherence, 
faster progression of the illness, disability and bed 
ridden state if we fail to detect it early. Even it can 
result in death in severe cases despite easier 
methods to screen the problem. 
It is important to study such problems in 
order to improve the well being and quality of life 
of HIV-positive people. Nevertheless, there is 
scarcity of studies on this research title in Ethiopia 
Therefore, the findings of this study might be 
valuable to different stakeholders, healthcare 
facilities and clinicians who are working in the 
scope. Thus, this study aimed at assessing the 
prevalence and factors associated with 
cognitive impairment among HIV-positive 
people attending at Ayder Comprehensive 
Specialized Hospital (ACSH), Mekelle, 
Ethiopia. 
 
METHODS AND SUBJECTS  
 
Mekelle is the capital city of Tigray 
Administrative Regional State located 783 kms 
North of Addis Ababa.  The city is divided into 
seven sub-administrative units, and it has one 
comprehensive specialized hospital (Ayder), two 
other public hospitals and one military hospital. A 
hospital based cross sectional study was conducted 
at Ayder Comprehensive Specialized Hospital 
between February and June 2016 (23). 
All HIV positive people who had follow up at 
the hospital were the source population. And, the 
study population included those participants who 
visited the hospital during the data collection 
period.  
The inclusion criteria was age between 18-64 
years (because age related neurocognitive deficit 
i.e. dementia starts from age of 65 years) and 
having documented HIV-positive status.  Those 
with known cognitive impairment unrelated to 
HIV (neurological, severe medical illnesses 
unrelated to HIV, severe mental illness) were 
excluded from the study.  
Sample size and sampling procedure: The actual 
sample size was determined by using the single 
population proportion formula where the 
following were considered: 95% confidence 
interval, 24.8% proportion of neurocognitive 
deficit among HIV positive patients (22) and 5% 
margin of error. Since the total population was 
1184, we e employed correction formula, and then 
added 10% estimated non-response rate that made 
a final sample size of 254.  
The participants were selected through 
systematic random sampling technique after 
having the monthly client flow to the hospital.  
Two psychiatric nurses were employed to collect 
data. Data were collected through face-to-face 
interview, observation and document review. 
Local language versions of International HIV 
dementia scale, activity of daily living scale and 
hospital anxiety and depression scale were used to 
assess neurocognitive deficit, activity of daily 
living, anxiety and depression respectively. These 
tools have been validated in sub-Saharan region, 
and HADS has been validated in Ethiopia, too, 
(24,25,26,27). 
Translation of the tools was carried out from 
their English version into local language version 
(Tigrigna) by professional translators, and the 
local language version was translated back into 
English by another professional with the help of a 
mental health specialist. Then, consistency was 
assured. Also, training was provided to the data 
collectors for one day on what information to 
gather and how to approach each client. A pretest 
was done at another public facility on 5% of the 
sample to check for necessary modifications. Also, 
daily supervision was employed during the data 
collection period. Daily data checkup and entry 
were also done. 
Operational definitions 
● HIV Associated Neurocognitive Deficit: It 
is a reduction or impairment of brain function;  
any patient who score less than or equal to 9.5 
from IHD scale (24) has this problem. 
● Activities of daily living: A score of 4 or less 
on Ketz Activity of Daily Living scale is 
considered to be a person impaired in his/her 
activity of daily living (25,26). 
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● Anxiety: A score of 8 or more on anxiety 
symptoms on Hospital Anxiety and Depression 
scale is considered that the person has anxiety 
(27). 
● Depression: A score of 8 or more of 
depression symptoms on Hospital Anxiety and 
Depression scale is considered that the person has 
depression (27). 
Data checkup, coding, entry and analysis were 
computed using SPSS window 20. To determine 
the degree of association between different 
variables and neurocognitive deficit, logistic 
regression was employed. Variables with p-value 
of 0.2 or less in the bivariete analysis were 
selected for multivariate analysis. The degree of 
association was determined with adjusted odds 
ratio (and 95% confidence interval). 
Ethical consideration: Ethical was obtained from 
Health Research Ethics Review Committee of the 
College of Health Sciences, Mekelle University. 
Permission was obtained from the hospital, and 
then consent was collected from the study 
participants before filling each questionnaire 
respecting their rights to withdraw from the study 
at any time. Confidentiality was assured for all the 
information provided, and no personal identifiers 
were used on the questionnaire. Participants who 
had neurocognitive deficit were resent to the 




A total of 234 HIV-positive people who had 
follow-up at Ayder Comprehensive Specialized 
Hospital participated in the study. Thus, the 
response rate was 92.1%. 
Socio-demographic characteristics: The 
respondents were predominantly females 
151(64.5%). The mean age (standard deviation)  
of participants was 38.26(+9.94) with a range of 
18 to 64 years.  The proportions of participants in 
the age group of 18 to 30 years, 31 to 40 years and 
above 40 years were 32.1% 34.1% and 33.8% 
respectively.  
Table 1: Socio demographic characteristics of HIV-positive people, Ayder Comprehensive Specialized 
Hospital, Ethiopia, June 2016 (n=234). 
 
 
Characteristics Frequency Percent  
Sex Female 151  64.5  
Male  83  35.5 
Age (years) 18-30 75 32 
31-40 80 34.2 
> 40 79 33.8 
Marital status Single 40 17.1 
Married 135 57.7 
Divorced 33 14.1 
Widowed 26 11.1 
Educational status No education 110 47 
Primary 61 26.1 
Secondary 30 12.8 
Higher education 33 14.1 
Occupation Laborer 48 20.5 
Civil servant   53  22.6  
Merchant  64 27.4 
Housewife  50 21.1 
Farmer  16 6.8 
Others  3 1.3 
Monthly income (Birr) <500  123 52.6 
501-1000   32  13.7  
1001-1500 50 21.1 
>1500 29 12.4 
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Educational status showed that 69(29.5%) of them 
were not able to read and write. Additionally, 
53(22.6%) and 64(27.4%) were daily laborers and 
government employee by occupation respectively. 
Married participants were 135(57.7%). Also, 
206(88%) and 169(72.2%) were Tigray by 
ethnicity and Orthodox Christian by religion 
respectively; 123(52.6%) of the respondents had a 
monthly income of 500 Birr or less (Table 1). 
Among 234 participants, 206(88%) were 
receiving HAART; about 54.3% were on follow-
up for 6 or more years. Also, 139(59.4%) patients 
were at stage 1 while 64(27.4%) were at stage 2 
according to WHO clinical staging. In addition, 
the recent CD4 count (within 3 months of the data 
collection period) was 351-500 cells/dl and 201-
350 cells/dl for about 32.9% and 31.2% of the 
subjects respectively. Opportunistic infections 
were observed in 14.5% of the participants. 
Besides, current use of psycho-active substances 
was reported in 13.7% of them (Table 2). 
 
Table 2: Clinical factors of HIV Positive People, Ayder Comprehensive Specialized Hospital, Ethiopia, 
June 2016 (n=234). 
 
 
Clinical factors Number  % 
CD4 count (cells/dl) <201 25  10.7 
201-350 73 31.2 
351-500 77 32.9 
>500 59 25.2 
Duration of illness 
(Years)  
 1 or less 29 12.4 
2- 4  78   33.3  
5 or more 127 54.3 
Clinical stage (WHO) Stage I 139 59.4 
Stage II  64   27.4  
Stage III 25 10.7 
Stage IV 6 2.6 
Status of HAART On HAART 206 88 
Pre-HAART 28 12 
Current OIs No 200 85.5 
Tuberculosis  17   7.4   
Pneumonia 3 1.3 
Others 14 6 
 
Magnitude of NCD: Of the study participants, 78 
scored 9.5 or less on IHDS. Thus, the magnitude 
of HIV associated neurocognitive deficit was 
33.3% (95% CI; 27.7% - 40.6%). The score on 
international HIV/AIDS dementia scale (IHDS) is 
as follows: 
The first part on IHDS is timed finger 
tapping. On this part, motor speed is assessed,  and 
107(45.7%) did well, scoring 4 out of 4. However, 
34(14.5%), 17(7.3%) and 9(3.8%) did worse, 
scoring 2/4, 1/4 and 0/4 respectively.  On the next 
part, which assessed psychomotor speed, 
125(53.4%) worked well without any impairment, 
scoring 4 out of 4, also 19 (8.1%), and 8(3.4%) 
scored one and zero out of 4 respectively. Memory 
recall was assessed in the third part, and it was 
found that 119(50.9%) recalled all the four things 
without any clue, scoring 4 out of 4, but about 
7(3%) could not recall all the things even with a 
clue, and they score zero out of 4. 
The magnitude across sex reveals that 34.4% 
of women and 31.3% of men developed NCD. 
Similarly, the problem increased with increment in 
age. Thus, it was 25%, 25.3% and 49.4% for the 
age groups of 18 - 30 years, 31 - 40 years and 
above 40 years respectively. Besides, it was 36.4% 
for unmarried participants. Concerning 
occupation, higher magnitude was observed for 
farmers and merchants with a proportion of 50% 
and 48.4% respectively. In the level of income, 
58.6% of participants who earned above 1500 Birr 
and 37.5% of those who earned 500 -100 Birr per 
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month had NCD while 36.4% of the participants 
who were on HAART had NCD, 39.4% of those 
on follow-up for 5 years or more had NCD. From 
the sub-group of clinical stages, 74.2% of the 
participants in clinical stages of stage 3 and stage 
4 developed NCD. Based on the CD4 count, it was 
found that 64% of them with 200 cells/dl or less 
had NCD; and 39.7% of the participants with a 
count of 201 - 350 cells/dl had NCD. Similarly, 
the magnitude of NCD among participants who 
had impairment in their activity of daily living, 
among those who developed anxiety and among 
those who had depression was 82.6%, 38.5% and 
37.6% respectively.   
Other independent factors: Activity of daily 
living was assessed using Katz Index of 
Independence in Activity of Daily Living, and we 
found that about 23(9.8%) of the participants had 
impairment in the function of activity of daily 
living. The levels of anxiety and depression as 
measured by Hospital Anxiety and Depression 
scale showed that 55.6% and 67.1% of HIV 
positive people had anxiety and depression 
respectively. 
Substance use assessment: Of the total 
participants, 32(13.7%) had used substance in the 
last three months. Alcohol was the commonest 
substance used by 14(6%) of them.  Both Tobacco 
and Khat use was also reported by 6(2.6%). Of 
substance users, about 11(34.3%) had HAND as 
determined by IHDS.   
Factors associated with neurocognitive deficit: 
Variables with p-value of 0.2 or less in the 
bivariate logistic regression were selected for 
multivariate analysis. The final degree of 
association as determined by adjusted odds ratio 
revealed that HIV-positive people who had 
impairment in their activity of daily living were 7 
times more prone to develop NCD (AOR= 7.19 
(95% CI;1.73, 21.83)). 
In a similar pattern, being in the 3
rd
 stage of 
HIV/AIDS was a risk for NCD compared to stage 
1. Thus, participants who were in the 3
rd
 stage 
were 4 times at risk of developing NCD compared 
to subjects in stage 1 (AOR= 4.2 (95% CI; 1.19, 
14.44)). Nonetheless, other socio-demographic 
characteristics, clinical factors, depression and 
anxiety were not significantly associated with 
NCD (Table 3). 
 
Table 3: Multivariate association between neuro cognitive deficit and other factors, ACSH, Mekelle, 




COR (95% CI) AOR (95% CI) 
Yes  No  
Depression Yes  59 98 1.84 (.99, 3.38) 1.15 (.49, 2.69) 
No  19 58 1 1 
Anxiety  Yes  50 80 1.69 (.97, 2.97) 1.04 (.48, 2.24) 
No  28 76 1 1 
Duration of Illness 
(in year) 
1  or less 8 21 1 1 
2-4   20 58 .9 (.35, 2.36) .84 (.29, 2.46) 
5 or more 50 77 1.7 (.70, 4.14) .79 (.38, 1.65 
Clinical stage Stage I 33 106 1 1 
Stage II 22 42 1.68 (.88, 3.21) 1.0 (.45, 2.24) 
Stage III 19 6 10.17 (3.75, 21.58) 4.2 (1.19, 14.44)* 
Stage IV 4 2 6.42 (1.13, 16.67) .61 (.04, 8.83) 
CD4 Count 
(Cells/dl) 
200 or less 16 9 6.29 (2.26, 17.49)  2.39 (.69, 8.29) 
201-350 29 44 2.33 (1.08, 5.06) 1.19 (.47, 3.04) 
351-500 20 57 1.24 (.56, 2.76) .93 (.39, 2.24) 
> 500 13 46 1 1 
Impairment in 
activity of daily 
living 
Yes  19 4 12.24 (3.99, 21.48) 7.19 (1.73, 21.83)* 
No  59 152 1 1 
Where COR=Crude odds ratio, CI=Confidence interval, CI=Confidence interval, *significantly associated 
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This study was undertaken to evaluate 
neurocognitive dysfunction in HIV patients using 
IHDS. In another study, among 234 patients, 
78(33.3%) had HAND. The prevalence of 
neurocognitive deficit in our study was higher 
than expected. Since most of our subjects were 
receiving treatment with HAART, higher 
prevalence might be observed. Yet, it is important 
to note that the high prevalence of neurocognitive 
deficit in this study may reflect the need for 
further refinement of the tool, IHDS, at national 
level. As compared to prior studies, the current 
finding is similar with the result of a study 
conducted in India (32.5%) (18), a study done in 
Nigeria (34.4%) [28] and an earlier Metaanalysis 
(systemic review) in Sub-Saharan area (30.9%) 
(2). However, it is less than the findings of 
previous studies undertaken in Botswana (38%) 
(21), a study in the international community (37%) 
(15), a study done in Cameroon (85%) [29], a 
study conducted in Asia (90%) (19) and a 
Ugandan study (46.49%) (30,31,32). 
Most of the participants among whom higher 
prevalence was reported might be in late stages of 
the illness by which neurocognitive impairment is 
more likely. Additionally, the other reason might 
be accounted to the difference in rating scales 
along with the variance in socio-demographic 
characteristics. However, the current finding is 
high compared to studies from Ethiopia (24.8%) 
and another study from Nigeria (21.5%) (17, 22). 
An earlier study from Ethiopia that employed 
IHDS determined the more severe form of 
neurocognitive deficit (HIV associated dementia). 
That could be the reason for the discrepancy. 
Other socio-demographic variations might also 
play a role for the inconsistency. 
This result is very high compared to multi- 
centered international studies (that were conducted 
at Thailand, Zaire, Kenya, Brazil and Germany). 
the problem was in a range of 13% to 19%. Also, 
this result is higher than the study in Malawi 
where prevalence of NCD was 15% (14, 15, 16, 
20). 
 Different viral clades and screening tools (or 
the questionnaire) used may account for the 
variation in the NCD as certain clades may be 
more or less neuropathogenic (33,34). Relatively, 
neurocognitive deficit is more prevalent in regions 
where subtype C HIV predominates. As one study 
reported, 60% of subjects with subtype C-HIV 
were found to have NCD although they have no 
functional impairment clinically (35, 36). 
The predominance of female participants in 
this study indicates that HIV/AIDS infection is 
more common in women than in men in Ethiopia. 
There are many reasons for this finding. These 
include cultural and economic factors that make 
women have little control over sexual and 
reproductive health issues. Another reason is that 
men do not come to the hospital either because of 
stigma or because they do not know their HIV 
status. Moreover, women are usually screened 
during antenatal visits as part of prevention of 
mother to child transmission of HIV. When found 
to be positive they are referred for treatment. 
Lastly, the finding of this study indicating that 
HIV infection is more common in women is 
similar with the observation made in Ethiopia. The 
result of this study showed that around 20.5% of 
the participants were unemployed, one-third of 
them had no education, and half of them had low 
level of monthly income which is similar with the 
country’s profile (37). 
Among those who had HIV associated 
neurocognitive deficit, one-fourth had depression 
as reported in a stud done in Botswana y (21). In 
our current study, as measured by HADS, more 
than half of the participants had depressive 
symptoms although it was not significantly 
associated with HAND.   
Furthermore, participants classified with 
neurocognitive impairment using the IHDS were 
basically asymptomatic in our study, since 
62(79.5%) out of 78 of those who had HAND did 
not report problems with daily activities or 
complain of cognitive problems. This might be 
alarming for clinicians and service providers to 
adopt and routinely screen HIV-positive people 
for possible NCD. 
Late clinical stage was a predictor for the 
onset of  NCD  in this study. This is supported by 
prior studies from Ethiopia in which all of the 
subjects in late stages were found to have HIV 
associated dementia (more severe form of 
HAND). Also, in a Nigerian study, it was 
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deducted that as the disease progresses more and 
viral load is increased, the probability of HAND is 
likely (17). In Uganda where 31% of the subjects 
had HIV associated dementia, lower CD4 count 
and advanced HIV disease were risk factors for 
cognitive decline (30,31,32). The study in 
Yaounde, Cameroon, which investigated risk 
factors for HIV associated neuricognitive deficit 
found that clinical factors of advanced clinical 
stage and lower CD4 count were predictors for 
HAND (38). 
We found that NCD was significantly 
associated with impairment in the activity of daily 
living. Previous studies in India, Nigeria and 
Malawi found that symptomatic neurocognitive 
deficits were found in 2.5%, 9% and 12% of the 
participants respectively (17,18,20). The more 
likely reason behind impaired daily functioning 
among HIV-positive people is NCD since it can 
impair motor activity besides memory and 
cognitive function (4,11).  
Different factors like older age, low level of 
education, lower level of hemoglobin, 
psychoactive substance use and opportunistic 
infections were mentioned as independent factors 
related to HIV associated NCD or HIV associated 
dementia in previous studies (17,18,19,20, 21,22). 
However, any of these factors did not show a 
significant association with NCD in our study. 
In spite of the finding showing that 38.5% 
and 37.6% of the participants who had anxiety and 
depression had already developed NCD 
respectively, neither anxiety nor depression was 
significantly associated with NCD in this study.  
We employed different standardized tools 
that help to determine the degree of association 
with the dependent variable. As a limitation, cause 
and effect relationship was not established 
between dependent and independent variables 
because of the cross sectional nature of the study. 
The finding reveals that regardless of the use 
of HAART, HIV associated neurocognitive 
deficits were common problems especially among 
participants in late stages of the illness. In 
addition,  it was significantly related with 
functional disability. Thus, it is highly crucial to 
prepare neurocognitive deficit screening tools at 
all clinical setups in order to recognize the 
problem early. Besides, it is vital for clinicians to 
routinely review the treatment regimen of patients 
and to monitor their clinical progress with special 
focus on those in late stages of the illness and 
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